
  
    
      
        Background_NNP
        Rhabdomyosarcoma_NNP is_VBZ a_DT malignant_JJ neoplasm_NN of_IN skeletal_NN
        muscle_NN ,_, and_CC is_VBZ one_CD of_IN the_DT most_RBS common_JJ soft_JJ tissue_NN
        malignancies_NNS in_IN the_DT children_NNS and_CC adolescent_JJ population_NN ._.
        Histopathologically_NNP rhabdomyosarcoma_NN can_MD be_VB divided_VBN into_IN
        two_CD major_JJ subtypes_NNS ,_, embryonal_NN rhabdomyosarcoma_NN representing_VBG
        about_IN 80_CD %_NN of_IN the_DT clinical_JJ cases_NNS ,_, and_CC alveolar_NN
        rhabdomyosarcoma_NN representing_VBG about_IN 20_CD %_NN of_IN the_DT total_JJ cases_NNS
        [_NN 1_CD 2_CD ]_NN ._. Extensive_NNP cytogenetic_JJ studies_NNS showed_VBD that_IN the_DT
        embryonal_NN rhabdomyosarcomas_NNS are_VBP generally_RB associated_VBN with_IN
        loss_NN of_IN heterozygosity_NN (_( LOH_NNP )_) for_IN multiple_JJ closely_RB linked_VBN
        loci_NN at_IN chromosomal_NN 11_CD p_NN 15_CD ._. 5_LS ,_, suggesting_VBG inactivation_NN of_IN one_CD
        or_CC more_RBR tumor-suppressor_JJ gene_NN (_( s_VBZ )_) in_IN this_DT region_NN [_NN 2_CD 3_CD ]_NN ._.
        But_CC the_DT gene_NN involved_VBN in_IN this_DT region_NN has_VBZ yet_RB to_TO be_VB
        identified_VBN ._. Many_JJ other_JJ associated_VBN mutation_NN or_CC amplification_NN
        of_IN oncogenes_NNS ,_, tumor_NN suppressor_NN genes_NNS including_VBG p_NN 53_CD ,_, K-_NNP ras_NNS ,_,
        N-_NNP ras_NNS and_CC N-_NNP myc_NN ,_, etc_FW ._. are_VBP frequently_RB seen_VBN ,_, but_CC the_DT roles_NNS of_IN
        these_DT gene_NN mutations_NNS /_NN amplifications_NNS in_IN pathogenesis_NNS of_IN the_DT
        tumor_NN remain_VB largely_RB unclear_JJ [_NN 4_CD ]_NN ;_: [_NN 5_CD ]_NN ._. The_DT alveolar_NN
        subtype_NN of_IN rhabdomyosarcoma_NN ,_, however_RB ,_, is_VBZ consistently_RB
        associated_VBN with_IN two_CD common_JJ chromosomal_NN translocations_NNS ._. Most_JJS
        cases_NNS of_IN alveolar_NN rhabdomyosarcoma_NN are_VBP associated_VBN with_IN a_DT
        chromosomal_NN translocation_NN t_NN (_( 2_CD ;_: 13_CD )_) (_( q_NN 35_CD ;_: q_NN 14_CD )_) ,_, and_CC less_RBR
        commonly_RB with_IN t_NN (_( 1_CD ;_: 13_CD )_) (_( p_NN 36_CD ;_: q_NN 14_CD )_) [_NN 6_CD 7_CD 8_CD 9_CD ]_NN ._. The_DT t_NN (_( 2_CD ;_: 13_CD )_)
        translocation_NN results_NNS in_IN fusion_NN of_IN a_DT portion_NN of_IN the_DT Pax_NNP 3_CD
        gene_NN to_TO a_DT portion_NN of_IN the_DT FKHR_NNP gene_NN ,_, leading_VBG to_TO formation_NN of_IN
        fusion_NN protein_NN Pax_NNP 3_CD -_: FKHR_NNP ._. Pax_NNP 3_CD gene_NN encodes_NNS a_DT
        transcriptional_NN factor_NN important_JJ in_IN early_JJ development_NN
        program_NN ,_, while_IN FKHR_NNP gene_NN encodes_NNS another_DT generic_JJ
        transcriptional_NN factor_NN that_WDT is_VBZ widely_RB expressed_VBN in_IN
        mammalian_JJ tissues_NNS ._. The_DT t_NN (_( 1_CD ;_: 13_CD )_) translocation_NN results_NNS in_IN
        formation_NN of_IN Pax_NNP 7_CD -_: FKHR_NNP ._. Both_DT Pax_NNP 3_CD -_: FKHR_NNP and_CC Pax_NNP 7_CD -_: FKHR_NNP were_VBD
        shown_VBN to_TO possess_VB more_RBR potent_JJ transcriptional_NN activity_NN than_IN
        its_PRP$ original_JJ forms_NNS Pax_NNP 3_CD and_CC Pax_NNP 7_CD [_NN 10_CD 11_CD ]_NN ._. How_WRB the_DT
        chimeric_JJ fusion_NN proteins_NNS contribute_VBP to_TO pathogenesis_NNS of_IN
        rhabdomyosarcoma_NN remains_VBZ unclear_JJ ._.
        Ataxia_NNP telangiectasia_NN mutated_VBN gene_NN (_( ATM_NNP )_) is_VBZ a_DT newly_RB
        identified_VBN member_NN of_IN PI_NNP 3_CD kinase_NN family_NN that_WDT is_VBZ mutated_VBN in_IN
        human_JJ autosomal_NN recessive_JJ disease_NN ,_, ataxia_NN telangiectasia_NN
        (_( AT_NNP )_) [_NN 12_CD 13_CD ]_NN ._. ATM_NNP gene_NN is_VBZ large_JJ ,_, spanning_VBG about_IN 150_CD kbs_NNS
        of_IN genomic_JJ DNA_NNP ,_, and_CC is_VBZ located_VBN on_IN chromosome_NN 11_CD q_NN 22_CD -_: 23_CD ._. In_IN
        response_NN to_TO DNA_NNP damage_NN agents_NNS such_JJ as_IN ionizing_VBG irradiation_NN
        and_CC chemical_NN agent_NN cisplatin_NN ,_, ATM_NNP kinase_NN is_VBZ activated_VBN ,_,
        leading_VBG to_TO a_DT cascade_NN of_IN kinase_NN reactions_NNS regulating_VBG cell_NN
        cycle_NN ,_, apoptosis_NNS ,_, and_CC DNA_NNP damage_NN repair_NN [_NN 14_CD 15_CD ]_NN ._. Many_JJ
        downstream_JJ target_NN molecules_NNS of_IN ATM_NNP kinase_NN were_VBD so_RB far_RB
        identified_VBN ._. These_DT target_NN proteins_NNS include_VBP the_DT c-_NN Abl_NNP
        tyrosine_NN kinase_NN ,_, the_DT p_NN 53_CD tumor_NN suppressor_NN ,_, the_DT Chk_NNP 1_CD and_CC
        Chk_NNP 2_CD serine_NN /_NN threoine_NN kinase_NN ,_, the_DT p_NN 34_CD subunit_NN of_IN replication_NN
        protein_NN A_DT (_( RPA_NNP )_) ,_, Chk_NNP 1_CD serine_NN /_NN threoine_NN kinase_NN and_CC NBS_NNP 1_CD
        kinase_NN which_WDT is_VBZ mutated_VBN in_IN human_JJ autosomal_NN recessive_JJ
        disease_NN Nijmegan_NNP breakage_NN syndrome_NN [_NN 16_CD 17_CD 18_CD 19_CD 20_CD 21_CD 22_CD
        23_CD ]_NN ._. Clinical_NNP characteristics_NNS of_IN AT_NNP patients_NNS include_VBP
        hypersensitivity_NN to_TO irradiation_NN ,_, thymic_JJ dysplasia_NN ,_, immune_JJ
        defects_NNS and_CC higher_JJR tendency_NN to_TO develop_VB malignant_JJ tumor_NN ,_,
        suggesting_VBG that_IN ATM_NNP function_NN is_VBZ critical_JJ in_IN DNA_NNP damage_NN
        repair_NN and_CC tumor_NN suppression_NN ._. However_RB ,_, up_RP to_TO date_NN ,_, AT_NNP
        patients_NNS are_VBP not_RB known_VBN to_TO develop_VB rhabdomyosarcoma_NN ._.
        In_IN this_DT study_NN ,_, we_PRP report_VBP an_DT association_NN of_IN human_JJ
        rhabdomyosarcoma_NN with_IN deletion_NN /_NN mutation_NN of_IN ATM_NNP gene_NN ._. This_DT
        is_VBZ the_DT first_JJ report_NN so_RB far_RB of_IN ATM_NNP gene_NN associated_VBN with_IN
        solid_JJ malignancy_NN except_IN for_IN the_DT mantle_NN cell_NN lymphoma_NN ,_, a_DT
        malignant_JJ tumor_NN in_IN lymphoid_NN origin_NN ._. The_DT association_NN of_IN ATM_NNP
        gene_NN mutation_NN /_NN deletion_NN with_IN rhabdomyosarcoma_NN suggests_VBZ a_DT
        link_NN of_IN ATM_NNP gene_NN with_IN cancer_NN risk_NN ,_, and_CC ATM_NNP kinase_NN may_MD
        contribute_VB to_TO pathogenesis_NNS of_IN rhabdomyosarcoma_NN ._.
      
      
        Results_NNS
        Totally_RB 17_CD patients_NNS specimen_NN were_VBD retrieved_VBN from_IN the_DT
        archived_JJ tissue_NN blocks_NNS ._. The_DT clinical_JJ characteristics_NNS of_IN
        these_DT patients_NNS were_VBD listed_VBN as_IN in_IN Table_NNP 1_CD ._. Some_DT patient_NN 's_POS
        clinical_JJ information_NN was_VBD not_RB available_JJ at_IN the_DT time_NN of_IN the_DT
        study_NN ._. These_DT patients_NNS all_DT carried_VBD clinical_JJ
        histopathological_JJ diagnoses_NNS of_IN rhabdomyosarcoma_NN (_( embryonal_NN
        or_CC alveolar_NN type_NN )_) ,_, and_CC showed_VBD immunostaining_VBG positivity_NN for_IN
        myogenin_NN ,_, a_DT specific_JJ skeletal_NN muscle_NN marker_NN ._.
        Immunofluorescent_NNP or_CC immunohistochemical_JJ staining_VBG with_IN
        anti-_NN ATM_NNP antibody_NN was_VBD performed_VBN on_IN the_DT total_NN of_IN 17_CD
        specimens_NNS ,_, and_CC 7_CD of_IN the_DT 17_CD rhabdomyosarcomas_NNS were_VBD negative_JJ
        for_IN ATM_NNP protein_NN (_( 41_CD %_NN )_) (_( see_VB Table_NNP 1_LS )_) ._. Totally_RB 10_CD of_IN the_DT 17_CD
        were_VBD positive_JJ for_IN ATM_NNP kinase_NN (_( 59_CD %_NN )_) ._. ATM_NNP protein_NN was_VBD
        predominantly_RB located_VBN in_IN cytoplasm_NN in_IN the_DT tumor_NN sections_NNS
        and_CC interestingly_RB ,_, predominantly_RB seen_VBN in_IN the_DT nuclei_NN in_IN the_DT
        rhabdomyosarcoma_NN cell_NN line_NN ,_, as_IN those_DT seen_VBN with_IN myoD_NN
        staining_VBG (_( RD_NNP cells_NNS )_) (_( Fig_NNP 1_CD and_CC 2_LS )_) ._. There_EX is_VBZ no_DT difference_NN in_IN
        staining_VBG pattern_NN in_IN regard_NN to_TO the_DT subtypes_NNS of_IN the_DT
        rhabdomyosarcomas_NNS ,_, namely_RB embryonal_NN or_CC alveolar_NN
        subtypes_NNS ._.
        It_PRP is_VBZ surprising_JJ to_TO note_VB that_IN 7_CD of_IN the_DT 17_CD (_( 41_CD %_NN )_)
        rhabdomyosarcoma_NN specimens_NNS stained_JJ negatively_RB for_IN the_DT
        presence_NN of_IN ATM_NNP protein_NN ._. Under_IN the_DT normal_JJ condition_NN ,_, ATM_NNP
        expression_NN is_VBZ ubiquitous_JJ ._. To_TO further_VB confirm_VB the_DT
        immunostaining_VBG results_NNS ,_, two_CD different_JJ approaches_NNS were_VBD
        taken_VBN ._. One_CD was_VBD to_TO see_VB if_IN the_DT ATM_NNP mRNA_NN is_VBZ properly_RB
        transcribed_JJ ,_, and_CC another_DT is_VBZ to_TO directly_RB see_VB the_DT ATM_NNP protein_NN
        itself_PRP by_IN Western_NNP blotting_VBG analysis_NN from_IN the_DT tumors_NNS and_CC
        compare_VB with_IN the_DT normal_JJ form_NN ._. Due_JJ to_TO the_DT limited_JJ resource_NN
        of_IN the_DT fresh_JJ tumor_NN samples_NNS ,_, we_PRP turned_VBD to_TO the_DT cell_NN culture_NN
        system_NN and_CC used_VBD the_DT well-established_JJ rhabdomyosarcoma_NN cell_NN
        lines_NNS ._. First_LS ,_, we_PRP designed_VBD eight_CD pairs_NNS of_IN oligonucleotide_NN
        primers_NNS encompassing_VBG the_DT almost_RB entire_JJ coding_VBG sequence_NN of_IN
        ATM_NNP mRNA_NN based_VBN on_IN the_DT published_VBN cDNA_NN sequence_NN (_( Genbank_NNP
        accession_NN number_NN U_NNP 33841_CD )_) [_NN 24_CD ]_NN (_( Table_NNP 2_LS )_) ._. The_DT primer_NN
        designing_VBG strategy_NN is_VBZ shown_VBN in_IN Fig_NNP 3_CD ._. ATM_NNP mRNA_NN is_VBZ
        approximately_RB 9_CD ._. 4_CD kbs_NNS in_IN length_NN and_CC contains_VBZ multiple_JJ
        protein_NN binding_JJ domains_NNS for_IN its_PRP$ kinase_NN activity_NN and_CC
        interaction_NN with_IN other_JJ cellular_JJ proteins_NNS (_( Fig_NNP 3_LS )_) ._. We_PRP used_VBD
        reverse_VB transcription-_NN PCR_NNP method_NN to_TO analyze_VB five_CD different_JJ
        rhabdomyosarcoma_NN cell_NN lines_NNS ,_, RD_NNP cells_NNS (_( embryonal_NN )_) ,_, Rh_NNP 28_CD ,_,
        Rh_NNP 30_CD (_( alveolar_NN )_) ,_, Rh_NNP 3_CD ,_, Rh_NNP 4_CD ,_, and_CC mouse_NN normal_JJ myoblast_NN C_NNP 2_CD C_NNP 12_CD
        cells_NNS ._. The_DT human_JJ foreskin_NN fibroblasts_NNS were_VBD used_VBN as_IN the_DT
        control_NN cells_NNS ._. The_DT mRNA_NN was_VBD isolated_VBN from_IN these_DT cells_NNS and_CC
        used_VBN for_IN RT-PCR_NNP assays_NNS ._. As_IN shown_VBN in_IN Fig_NNP 4_CD ,_, in_IN normal_JJ
        fibroblasts_NNS ,_, RD_NNP cells_NNS ,_, Rh_NNP 28_CD cells_NNS ,_, the_DT amplified_VBN DNA_NNP
        fragments_NNS were_VBD identical_JJ in_IN regard_NN to_TO the_DT lengths_NNS in_IN
        comparing_VBG with_IN the_DT control_NN fibroblasts_NNS ,_, whereas_IN in_IN Rh_NNP 30_CD
        cells_NNS ,_, two_CD fragments_NNS in_IN #_# 1_CD and_CC #_# 7_CD lanes_NNS (_( 0_CD ._. 94_CD kbs_NNS in_IN Lane_NNP
        #_# 1_CD ,_, and_CC 1_CD ._. 3_CD kbs_NNS in_IN Lane_NNP #_# 7_CD )_) were_VBD absent_JJ ,_, and_CC in_IN lane_NN #_# 6_CD ,_,
        the_DT fragment_NN amplified_VBN was_VBD approximately_RB 200_CD bps_NNS smaller_JJR
        than_IN that_DT seen_VBN in_IN the_DT fibroblasts_NNS and_CC other_JJ
        rhabdomyosarcoma_NN cells_NNS (_( Fig_NNP 4_LS )_) ._. The_DT combined_VBN length_NN of_IN
        missing_VBG DNA_NNP sequence_NN is_VBZ estimated_VBN 2_CD ._. 4_CD kb_NN (_( fragment_NN #_# 1_CD ,_, plus_CC
        fragment_NN #_# 7_CD ,_, and_CC additional_JJ 200_CD bps_NNS in_IN lane_NN #_# 6_CD )_) ._.
        The_DT next_JJ question_NN is_VBZ whether_IN ATM_NNP protein_NN is_VBZ normally_RB
        translated_VBN from_IN ATM_NNP mRNA_NN and_CC expressed_VBD in_IN the_DT
        rhabdomyosarcoma_NN cells_NNS ._. We_PRP analyzed_VBD the_DT ATM_NNP protein_NN in_IN
        different_JJ cell_NN lines_NNS ._. In_IN human_JJ Hela_NNP cells_NNS and_CC human_JJ normal_JJ

        foreskin_NN fibroblasts_NNS ,_, the_DT ATM_NNP was_VBD estimated_VBN to_TO be_VB 360_CD kD_NN ,_,
        consistent_JJ with_IN the_DT results_NNS previously_RB described_VBD [_NN 12_CD 13_CD ]_NN
        ._. In_IN three_CD rhabdomyosarcoma_NN cell_NN lines_NNS (_( RD_NNP ,_, Rh_NNP 28_CD and_CC RH_NNP 30_CD )_) ,_,
        there_EX was_VBD one_CD aberrant_NN form_NN of_IN ATM_NNP protein_NN (_( ~_NN 260_CD kD_NN )_) that_WDT
        was_VBD significantly_RB smaller_JJR than_IN that_DT seen_VBN in_IN the_DT normal_JJ
        fibroblasts_NNS and_CC the_DT Hela_NNP cells_NNS (_( Fig_NNP 5_LS )_) ._. The_DT levels_NNS of_IN ATM_NNP
        expression_NN in_IN these_DT three_CD rhabdomyosarcoma_NN cell_NN lines_NNS are_VBP
        not_RB identical_JJ ,_, and_CC Rh_NNP 30_CD cells_NNS seemed_VBD to_TO express_VB less_JJR ATM_NNP
        than_IN the_DT other_JJ two_CD Rhabdomyosarcoma_NNP cells_NNS ._. The_DT murine_NN ATM_NNP
        proteins_NNS from_IN C_NNP 2_CD C_NNP 12_CD and_CC 10_CD T_NN 1_CD /_NN 2_CD cells_NNS were_VBD significantly_RB
        different_JJ in_IN size_NN and_CC there_EX appeared_VBD to_TO be_VB two_CD species_NNS of_IN
        ATM_NNP proteins_NNS in_IN murine_NN cells_NNS ._.
      
      
        Discussion_NNP
        ATM_NNP gene_NN is_VBZ a_DT member_NN of_IN PI_NNP 3_CD kinase_NN family_NN ._. ATM_NNP kinase_NN is_VBZ
        critical_JJ in_IN DNA_NNP damage_NN signaling_VBG pathway_NN ._. In_IN response_NN to_TO
        DNA_NNP damage_NN induced_VBN by_IN ionizing_VBG radiation_NN or_CC chemical_NN agents_NNS
        such_JJ as_IN cisplatin_NN ,_, ATM_NNP kinase_NN is_VBZ activated_VBN and_CC
        phosphorylates_NNS a_DT number_NN of_IN downstream_JJ regulatory_JJ proteins_NNS
        important_JJ for_IN cell_NN cycle_NN arrest_NN ,_, growth_NN control_NN ,_, apoptosis_NNS
        and_CC DNA_NNP repair_NN [_NN 25_CD 26_CD 27_CD 28_CD ]_NN ._. AT_NNP patients_NNS are_VBP known_VBN to_TO
        be_VB predisposed_JJ to_TO a_DT variety_NN of_IN cancers_NNS ,_, and_CC the_DT fibroblasts_NNS
        of_IN AT_NNP patients_NNS are_VBP hypersensitive_JJ to_TO ionizing_VBG radiation_NN [_NN
        29_CD ]_NN ._. Although_IN many_JJ reports_NNS showed_VBD the_DT association_NN of_IN ATM_NNP
        mutation_NN with_IN risk_NN of_IN a_DT number_NN of_IN different_JJ human_JJ
        malignancies_NNS ,_, including_VBG prostate_NN cancer_NN ,_, breast_NN cancer_NN ,_,
        ovarian_NN cancer_NN ,_, B-_NNP cell_NN chronic_JJ lymphocytic_JJ leukemia_NN and_CC
        mantle_NN cell_NN lymphoma_NN ,_, the_DT underlying_VBG molecular_JJ mechanism_NN by_IN
        which_WDT ATM_NNP gene_NN causes_NNS these_DT changes_NNS are_VBP not_RB well_RB understood_VBN
        [_NN 30_CD 31_CD 32_CD 33_CD 34_CD 35_CD ]_NN ._. There_EX is_VBZ so_RB far_RB no_DT study_NN showing_VBG
        the_DT association_NN of_IN ATM_NNP gene_NN with_IN any_DT solid_JJ tumor_NN ._. There_EX is_VBZ
        enormous_JJ epidemiological_JJ interest_NN in_IN establishing_VBG the_DT link_NN
        of_IN ATM_NNP gene_NN abnormality_NN with_IN cancer_NN risk_NN ,_, since_IN the_DT
        percentage_NN of_IN the_DT ATM_NNP heterozygotes_NNS is_VBZ high_JJ ,_, and_CC estimated_VBD
        to_TO represent_VB 1_CD ._. 5_CD %_NN of_IN total_JJ population_NN ._.
        We_PRP studied_VBD the_DT immunostaining_VBG characteristics_NNS of_IN ATM_NNP
        protein_NN in_IN clinical_JJ rhabdomyosarcoma_NN cases_NNS and_CC found_VBD that_IN a_DT
        significantly_RB high_JJ number_NN of_IN cases_NNS lacked_VBD the_DT proper_JJ ATM_NNP
        gene_NN product_NN (_( 41_CD %_NN in_IN 17_CD cases_NNS )_) ._. The_DT clinical_JJ significance_NN
        of_IN this_DT finding_VBG is_VBZ unclear_JJ at_IN this_DT point_NN ._. There_EX is_VBZ high_JJ
        percentage_NN of_IN clinical_JJ rhabdomyosarcoma_NN cases_NNS associated_VBN
        with_IN p_NN 53_CD gene_NN mutation_NN /_NN deletion_NN ._. The_DT p_NN 53_CD mutant_JJ mice_NNS tend_VBP
        to_TO develop_VB rhabdomyosarcoma_NN [_NN 29_CD ]_NN ._. P_NN 53_CD is_VBZ a_DT tumor_NN
        suppressor_NN regulating_VBG cell_NN cycle_NN control_NN and_CC apoptosis_NNS ,_, and_CC
        p_NN 53_CD is_VBZ one_CD of_IN the_DT many_JJ downstream_JJ targets_NNS of_IN ATM_NNP kinase_NN [_NN
        25_CD 27_CD ]_NN ._. ATM_NNP phosphorylate_NN p_NN 53_CD at_IN Serine_NNP 15_CD in_IN response_NN to_TO
        DNA_NNP damage_NN agents_NNS [_NN 17_CD ]_NN ._. It_PRP is_VBZ unknown_JJ how_WRB the_DT mutated_VBN
        ATM_NNP contributes_VBZ to_TO pathogenesis_NNS of_IN rhabdomyosarcoma_NN in_IN the_DT
        presence_NN of_IN the_DT mutated_VBN p_NN 53_CD ._. In_IN fact_NN ,_, the_DT rhabdomyosarcoma_NN
        cells_NNS Rh_NNP 30_CD is_VBZ known_VBN to_TO have_VB p_NN 53_CD mutation_NN ,_, and_CC is_VBZ also_RB
        positive_JJ for_IN t_NN (_( 2_CD ;_: 13_CD )_) chromosomal_NN translocation_NN [_NN 11_CD ]_NN ._.
        Further_RB investigations_NNS are_VBP needed_VBN to_TO address_VB these_DT
        important_JJ questions_NNS ._.
        The_DT finding_NN of_IN ATM_NNP protein_NN predominantly_RB present_JJ in_IN the_DT
        cytoplasm_NN ,_, but_CC not_RB the_DT nucleus_NN of_IN the_DT tumor_NN sections_NNS
        suggests_VBZ a_DT different_JJ role_NN of_IN ATM_NNP in_IN the_DT tumor_NN cells_NNS ._. In_IN the_DT
        tumor_NN cell_NN lines_NNS ,_, the_DT ATM_NNP protein_NN is_VBZ present_JJ predominantly_RB
        in_IN the_DT nucleus_NN ._. The_DT underlying_VBG significance_NN of_IN this_DT finding_VBG
        is_VBZ unclear_JJ ._. Presumably_RB ATM_NNP protein_NN in_IN the_DT cytoplasm_NN may_MD
        function_VB differently_RB in_IN the_DT tumor_NN cells_NNS in_IN vivo_NN from_IN that_DT
        in_IN the_DT nucleus_NN seen_VBN in_IN the_DT cell_NN culture_NN ._.
        The_DT murine_NN ATM_NNP was_VBD found_VBN significantly_RB different_JJ in_IN
        size_NN ,_, although_IN the_DT ATM_NNP knockout_NN mice_NNS recapitulate_NN the_DT
        phenotypic_JJ features_NNS of_IN A-T_NNP patients_NNS [_NN 36_CD ]_NN ._. This_DT species_NNS
        difference_NN may_MD be_VB important_JJ in_IN interpreting_VBG the_DT data_NNS from_IN
        human_JJ cells_NNS and_CC from_IN murine_NN cells_NNS ._.
      
      
        Methods_NNP
        
          Immunohistochemical_NNP and_CC immunofluorescent_NN
          staining_VBG
          Human_JJ rhabdomyosarcoma_NN tumor_NN specimens_NNS were_VBD obtained_VBN
          from_IN the_DT Department_NNP of_IN Pathology_NNP ,_, the_DT Children_NNP 's_POS Hospital_NNP
          San_NNP Diego_NNP ._. All_DT human_JJ tissues_NNS were_VBD formalin_NN fixed_VBD ,_,
          paraffin_NN embedded_VBN and_CC were_VBD previously_RB used_VBN for_IN diagnostic_JJ
          purposes_NNS ._. Current_JJ study_NN was_VBD approved_VBN by_IN the_DT Institutional_NNP
          Review_NNP Board_NNP at_IN University_NNP of_IN California_NNP ,_, San_NNP Diego_NNP
          (_( IRB_NNP )_) ._. The_DT specimens_NNS were_VBD sectioned_JJ at_IN 5_CD micron_NN in_IN
          thickness_NN ,_, and_CC used_VBD for_IN immunohistochemical_JJ staining_VBG with_IN
          ATM_NNP antibody_NN as_IN described_VBN [_NN 18_CD ]_NN ._. Briefly_NNP ,_, the_DT sections_NNS
          were_VBD de-paraffinized_JJ in_IN xylene_NN solution_NN ,_, de-hydrated_JJ and_CC
          rehydrated_JJ in_IN 100_CD %_NN ,_, 90_CD %_NN and_CC 70_CD %_NN alcohol_NN ._. The_DT specimens_NNS
          were_VBD immersed_VBN in_IN Antigen_NNP Retrieval_NNP solution_NN (_( commercially_RB
          available_JJ from_IN Dako_NNP Corp_NNP ._. CA_NNP )_) at_IN 90_CD °_NN C_NNP for_IN 30_CD minutes_NNS to_TO
          unmask_VB the_DT antigen_NN followed_VBN by_IN incubation_NN with_IN primary_JJ
          antibody_NN against_IN ATM_NNP protein_NN at_IN 4_CD °_NN C_NNP overnight_JJ ._. The_DT
          primary_JJ anti-_NN ATM_NNP antibody_NN was_VBD kindly_RB provided_VBN by_IN Dr_NNP ._.
          Gately_NNP and_CC as_IN described_VBN previously_RB [_NN 18_CD ]_NN ._. The_DT second_JJ
          antibody_NN was_VBD either_CC immuno-peroxidase_JJ conjugated_JJ for_IN
          immunochemical_JJ stains_NNS or_CC Cy_NNP 3_CD conjugated_JJ anti-rabbit_JJ IgG_NNP
          for_IN immunofluorescent_NN stains_NNS (_( Molecular_NNP Probes_NNP ,_, OR_NNP )_) ._. For_IN
          immunofluorescent_NN staining_VBG for_IN the_DT tumor_NN cell_NN lines_NNS ,_, the_DT
          tumor_NN cells_NNS were_VBD cultured_JJ on_IN the_DT glass_NN coverslips_NNS ,_, fixed_VBN
          by_IN 4_CD %_NN paraformaldehyde_NN and_CC stained_JJ with_IN primary_JJ antibody_NN
          against_IN ATM_NNP and_CC MyoD_NNP as_IN described_VBN [_NN 37_CD ]_NN ._.
        
        
          Cell_NNP culture_NN ,_, RNA_NNP isolation_NN ,_, reverse_VB transcription_NN
          and_CC PCR_NNP
          Rhabdomyosarcoma_NNP cell_NN lines_NNS ,_, such_JJ as_IN Rh_NNP 3_CD ,_, Rh_NNP 4_CD ,_, Rh_NNP 28_CD ,_,
          RH_NNP 30_CD and_CC RD_NNP cells_NNS were_VBD obtained_VBN from_IN Dr_NNP ._. Karen_NNP Arden_NNP ,_,
          Ludwig_NNP Institute_NNP of_IN Cancer_NNP Research_NNP at_IN UCSD_NNP ._. The_DT tumor_NN
          cell_NN lines_NNS were_VBD cultured_JJ and_CC maintained_VBN as_IN described_VBN [_NN 37_CD
          ]_NN ._. The_DT total_JJ RNA_NNP was_VBD isolated_VBN from_IN the_DT cultured_JJ cells_NNS
          using_VBG Trizol_NNP RNA_NNP isolation_NN kit_NN (_( GBCOL-BRL_NNP ,_, Besthesda_NNP ,_,
          MD_NNP )_) ._. The_DT cDNA_NN synthesis_NN was_VBD performed_VBN using_VBG the_DT cDNA_NN
          synthesis_NN kit_NN (_( Supersccript_NNP ,_, GBCOL-BRL_NNP )_) using_VBG random_JJ
          hexamer_NN and_CC oligo-d_JJ (_( T_NN )_) primers_NNS following_VBG the_DT instruction_NN
          from_IN the_DT manufacturer_NN ._. The_DT total_JJ cDNA_NN was_VBD directly_RB used_VBN
          as_IN templates_NNS for_IN PCR_NNP amplification_NN for_IN ATM_NNP gene_NN using_VBG the_DT
          primer_NN pairs_NNS in_IN Table_NNP 2_CD ._. The_DT primer_NN sequences_NNS were_VBD based_VBN
          on_IN the_DT ATM_NNP sequence_NN (_( Genbank_NNP accession_NN number_NN U_NNP 33841_CD )_) ,_,
          and_CC were_VBD described_VBN for_IN mantle_NN cell_NN lymphoma_NN with_IN slight_JJ
          modification_NN [_NN 24_CD ]_NN ._. The_DT primers_NNS were_VBD synthesized_JJ by_IN
          Sigma-_NNP Genosys_NNP (_( Woodlands_NNP ,_, Texas_NNP )_) ._. The_DT PCR_NNP products_NNS were_VBD
          electrophoresed_JJ in_IN 1_CD %_NN agarose_NN gel_NN and_CC visualized_JJ using_VBG
          ethidium_NN bromide_NN staining_VBG ._.
        
        
          Western_NNP blotting_VBG of_IN ATM_NNP protein_NN
          The_DT rhabdomyosarcoma_NN cells_NNS are_VBP cultured_JJ and_CC maintained_VBN
          as_IN described_VBN [_NN 37_CD ]_NN ._. The_DT cellular_JJ proteins_NNS were_VBD
          prepared_VBN ,_, separated_JJ on_IN 4_CD %_NN polyacrylamide_NN gel_NN and_CC
          transferred_VBN onto_IN nitrocellulose_NN membrane_NN ._. The_DT immobilized_JJ
          proteins_NNS were_VBD incubated_JJ with_IN anti-_NN ATM_NNP antibody_NN [_NN 18_CD ]_NN ._.
          The_DT proteins_NNS of_IN interest_NN were_VBD detected_VBN by_IN enhanced_JJ
          immunochemiluminescence_NN kit_NN from_IN Amersham_NNP Life_NNP Sciences_NNPS [_NN
          37_CD ]_NN ._.
        
      
      
        Author_NN 's_POS contributions_NNS
        PZ_NNP designed_VBD and_CC analyzed_VBN the_DT data_NNS ,_, and_CC performed_VBD large_JJ
        portion_NN of_IN the_DT experiments_NNS ._. KB_NNP helped_VBD in_IN protein_NN
        extractions_NNS and_CC Western_JJ blot_NN analyses_NNS ._. PLP_NNP ,_, JF_NNP and_CC JW_NNP
        participated_VBD with_IN extensive_JJ discussion_NN of_IN design_NN and_CC
        experiments_NNS ._. RON_NNP reviewed_VBD all_PDT the_DT patient_NN 's_POS tumor_NN staining_VBG
        and_CC patients_NNS cases_NNS for_IN diagnoses_NNS ._. All_DT authors_NNS read_VBP the_DT
        final_JJ manuscripts_NNS ._.
      
    
  
